Cendifensine - Noema Pharma
Alternative Names: NOE-115Latest Information Update: 28 Jan 2026
At a glance
- Originator Roche
- Developer Noema Pharma
- Class Alkanes; Antidepressants; Behavioural disorder therapies; Chlorobenzenes; Ketones; Pyrrolidines; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Vasomotor symptoms
- No development reported Binge-eating disorder; Depressive disorders
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for phase-I development in Binge-Eating-Disorder in Switzerland (Parenteral)
- 28 Jan 2026 No recent reports of development identified for phase-I development in Depressive disorders in Switzerland (Parenteral)
- 17 Nov 2025 Chemical structure information added.